Vaccine immunotherapy
The present invention provides compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions. According to one embodiment of the invention, a composition is provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion, the composition comprising an effective amount of a cytokine mixture, preferably comprising IL-1, IL-2, IL-6, IL-8, IFN-γ (gamma) and TNF-α (alpha). The cytokine mixture acts as an adjuvant with the antigen associated with the antigen-producing disease or lesion to enhance the immune response of the patient to the antigen. Methods are therefore also provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion utilizing the cytokine mixture of the invention. The compositions and methods are useful in the treatment of antigen-producing diseases such as cancer, infectious diseases or persistent lesions.
1. A method of immunotherapy to treat cancer in a patient comprising:
administering an effective amount of a cytokine mixture comprising IL-1, IL-2, IL-6, IL-8, IFN-γ, and TNF-α to the patient; and
administering an effective amount of at least one exogenous tumor peptide antigen to the patient,
wherein the cytokine mixture acts as an adjuvant and stimulates in the patient an enhanced antigen-specific immune response to the at least one exogenous tumor peptide antigen.
2. The method of claim 1 , wherein the cytokine mixture and the at least one exogenous tumor peptide antigen are administered at or near the same site.
3. The method of claim 2 , wherein the cytokine mixture is administered to the patient before the at least one exogenous tumor peptide antigen.
4. The method of claim 2 , wherein the cytokine mixture is administered to the patient after the at least one exogenous tumor peptide antigen.
5. The method of claim 2 , wherein the cytokine mixture and the at least one exogenous tumor peptide antigen are administered at the same time.
6. The method of claim 5 , wherein the cytokine mixture and the at least one exogenous tumor peptide antigen are in the same pharmacological preparation.
7. The method of claim 1 , wherein the cytokine mixture comprises natural cytokines.
8. The method of claim 7 , wherein the IL-1 is present in an amount of 60-6,000 picograms (pcg)/mL, the IL-2 is present in an amount of 600-60,000 pcg/mL, the IL-6 is present in an amount of 60-6,000 pcg/mL, the IL-8 is present in an amount of 6,000-600,000 pcg/mL, the IFN-γ is present in an amount of 200-20,000 pcg/mL, and the TNF-α is present in an amount of 200-20,000 pcg/mL.
9. The method of claim 1 , wherein the administering to the patient occurs in or near a lymph node regional to a tumor.
10. The method of claim 1 , wherein the administering to the patient occurs around lymphatics that drain into lymph nodes regional to the tumor.
11. The method of claim 1 , wherein the administering to the patient occurs more than once.
12. The method of claim 1 , wherein the method further comprises:
administering an effective amount of a cyclophosphamide to the patient.
13. The method of claim 1 , wherein the method further comprises:
administering an effective amount of a non-steroidal anti-inflammatory drug to the patient.
14. The method of claim 1 , wherein the method further comprises:
administering an effective amount of zinc to the patient.
15. The method of claim 1 , wherein the method further comprises:
administering an effective amount of a cyclophosphamide to the patient; and
administering an effective amount of a non-steroidal anti-inflammatory drug to the patient.
16. The method of claim 1 , wherein the administering of the cytokine mixture and the at least one exogenous tumor peptide antigen occurs before or after surgery, radiotherapy, chemotherapy, or combinations thereof.
17. The method of claim 1 , wherein the at least one exogenous tumor peptide antigen is at least one prostate specific membrane antigen (PSMA) peptide.